|
|
DRUG INTERACTIONS
No formal drug interaction studies have been conducted with Rebif® . Due to its potential to cause neutropenia and lymphopenia, proper monitoring of patients is required if Rebif® is given in combination with myelosuppressive agents.
|
OVERDOSAGE
Safety of doses higher than 44 mcg sc tiw has not been adequately evaluated. The maximum amount of Rebif® that can be safely administered has not been determined.
|
CONTRAINDICATIONS
Rebif® (interferon beta-1a) is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon, human albumin, or any other component of the formulation.
|
REFERENCES
-
PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon (beta)-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
-
Data on file.
Manufacturer: Serono, Inc. Rockland, MA 02370
U.S. License # 1574
Co-Marketed by:
Serono, Inc.
Rockland, MA 02370
Pfizer Inc.
New York, NY 10017
Revised: March 2004
* Avonex® is a registered trademark of Biogen, Inc.
N6700101B 04/04
|
|
|
|
-- advertisement --
|
